ENYO Pharma ("ENYO"), a clinical-stage biopharmaceutical company developing innovative therapies for kidney diseases, today ...

A normal echocardiogram doesn't always mean a healthy heart. Persistent symptoms like breathlessness and fatigue can indicate ...

In a retrospective study, repetitive transcranial magnetic stimulation produces weight loss comparable to semaglutide 0.5 ...

And in a phase III trial win, Foresee Pharmaceuticals said its long-acting gonadotropin-releasing hormone agonist leuprolide ...

Q: My son, age 10, and daughter, age 14, are putting on extra pounds. But they won’t listen to me when I say, “Don’t eat that ...

A large population-based study found that adults with type 2 diabetes (T2D) who start treatment with sodium–glucose ...

A major pooled analysis published in JAMA has shown that sodium-glucose cotransporter 2 (SGLT2) inhibitors deliver consistent ...

At the 2025 AMCP annual meeting in Houston, John M. O'Brien, Pharm.D., M.P.H., president and CEO of the National ...

A recent review examined how widely used treatments such as metformin, SGLT2 inhibitors, and GLP-1 receptor agonists may ...

Meanwhile, in attempts to address long-standing thyroid cancer concerns, a research team conducted a 350,000-person analysis ...

New research released January 1, 2026, shows two heart drugs together may treat fatty liver disease, offering a potential breakthrough for millions battling NASH ...